Journal Mobile Options
Table of Contents
Vol. 98, No. 2-3, 2002
Issue release date: 2002
Cytogenet Genome Res 98:126–135 (2002)

Reverse mosaicism in Fanconi anemia: natural gene therapy via molecular self-correction

Gross M. · Hanenberg H. · Lobitz S. · Friedl R. · Herterich S. · Dietrich R. · Gruhn B. · Schindler D. · Hoehn H.
aDepartment of Human Genetics, University of Würzburg, Würzburg; bDepartment of Pediatrics, University of Düsseldorf, Düsseldorf; cDeutsche Fanconi Hilfe e.V., Unna-Siddinghausen; dDepartment of Pediatrics, University of Jena, Jena (Germany)

Individual Users: Register with Karger Login Information

Please create your User ID & Password

Contact Information

I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in


Fanconi anemia (FA) is a genetically and phenotypically heterogenous autosomal recessive disease associated with chromosomal instability and hypersensitivity to DNA crosslinkers. Prognosis is poor due to progressive bone marrow failure and increased risk of neoplasia, but revertant mosaicism may improve survival. Mechanisms of reversion include back mutation, intragenic crossover, gene conversion and compensating deletions/insertions. We describe the types of reversions found in five mosaic FA patients who are compound heterozygotes for single base mutations in FANCA or FANCC. Intragenic crossover could be shown as the mechanism of self-correction in the FANCC patient. Restoration to wildtype via back mutation or gene conversion of either the paternal or maternal allele was observed in the FANCA patients. The sequence environments of these mutations/reversions were indicative of high mutability, and selective advantage of bone marrow precursor cells carrying a completely restored FANCA allele might explain the surprisingly uniform pattern of these reversions. We also describe a first example of in vitro phenotypic reversion via the emergence of a compensating missense mutation 15 amino acids downstream of the constitutional mutation, which explains the reversion to MMC resistance of the respective lymphoblastoid cell line. With one exception, our mosaic patients showed improvement of their hematological status during a three- to six-year observation period, indicating a proliferative advantage of the reverted cell lineages. In patients with Fanconi anemia, genetic instability due to defective caretaker genes sharply increases the risk of neoplasia, but at the same time increases the chance for revertant mosaicism leading to improved bone marrow function.    

Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.


  1. Bullock P, Champoux JJ, Botchan M: Association of crossover points with topoisomerase I cleavage sites: a model for nonhomologous recombination. Science 230:954–958 (1975).
  2. Cahill DP, Kinzler KW, Vogelstein B, Lengauer C: Genetic instability and Darwinian selection in tumours. Trends Cell Biol 12:57–60 (1999).
  3. Cooper DN, Krawcak M: Human Gene Mutation (BIOS Scientific Publishers, Oxford 1993).
  4. de Boer J, Andressoo JO, de Wit J, Huijmans J, Beems RB, van Steeg H, Weeda G, van der Horst GT, van Leeuwen W, Themmen AP, Meradji M, Hoeijmakers JH: Premature aging in mice deficient in DNA repair and transcription. Science 296:1276–1279 (2002).
  5. Ellis NA, Ciocci S, German J: Back mutation can produce phenotype reversion in Bloom syndrome somatic cells. Hum Genet 108:167–173 (2001).
  6. Ellis NA, Lennon DJ, Proytcheva M, Alhadeff B, Henderson EE, German J: Somatic intragenic recombination within the mutated locus BLM can correct the high sister-chromatid exchange phenotype of Bloom syndrome cells. Am J hum Genet 57:1019–1027 (1995) and erratum Am J hum Genet 58:254 (1996).
  7. Faivre L, Guardiola P, Lewis C, Dokal I, Ebell W, Zatterale A, Altay C, Poole J, Stones D, Kwee ML, van Weel-Sipman M, Havenga C, Morgan N, de Winter J, Digweed M, Savoia A, Pronk J, de Ravel T, Jansen S, Joenje H, Gluckman E, Mathew CG: Association of complementation group and mutation type with clinical outcome in Fanconi anemia. European Fanconi Anemia Research Group. Blood 96:4064–4070 (2000).
  8. Gillio AP, Verlander PC, Batish SD, Giampietro PF, Auerbach AD: Phenotypic consequences of mutations in the Fanconi anemia FAC gene: an International Fanconi Anemia Registry study. Blood 90:105–110 (1997).
  9. Gottlieb B, Beitel LK, Trifiro MA: Somatic mosaicism and variable expressivity. Trends Genet 17:79–82 (2001).
  10. Gregory JJ, Wagner JE, Verlander PC, Levran O, Batish SD, Eide CR, Steffenhagen A, Hirsch B, Auerbach AD: Somatic mosaicism in Fanconi anemia: evidence of genotypic reversion in lymphohematopoietic stem cells. Proc natl Acad Sci, USA 98:2532–2537 (2001).
  11. Haaf T, Steinlein K, Schmid M: Preferential somatic pairing between homologous heterochromatic regions of human chromosomes. Am J hum Genet 38:319–329 (1986).
  12. Hanenberg H, Batish SD, Pollok KE, Vieten L, Verlander PC, Leurs C, Cooper RJ, Göttsche K, Haneline L, Clapp DW, Lobitz S, Williams DA, Auerbach AD: Phenotypic correction of primary Fanconi anemia T cells with retroviral vectors as a diagnostic tool. Exp Hematol 30:1–11 (2002).
  13. Hanenberg H, Hashino K, Konishi H, Hock RA, Kato I, Williams DA: Optimization of fibronectin-assisted retroviral gene transfer into human CD34+ hematopoietic cells. Hum Gene Ther 8:2193–2206 (1997).
  14. Hanenberg H, Xiao XL, Dilloo D, Hashino K, Kato I, Williams DA: Colocalization of retrovirus and target cells on specific fibronectin fragments increases genetic transduction of mammalian cells. Nature Med 2:876–882 (1996).
  15. Hawley RG, Lieu FHL, Fong AZC, Hawley TS: Versatile retroviral vectors for potential use in gene therapy. Gene Therapy 1:136–138 (1994).
  16. Howlett NG, Taniguchi T, Olson S, Cox B, Waisfisz Q, De Die-Smulders C, Persky, N, Grompe M, Joenje H, Pals G, Ikeda H, Fox EA, D’Andrea AD: Biallelic inactivation of BRCA2 in Fanconi anemia. Science 297:606–609 (2002).
  17. Hirschhorn R, Yang DR, Puck JM, Huie ML, Jiang C-K, Kurlandsky EL: Spontaneous in vivo reversion to normal of an inherited mutation in a patient adenosine deaminase deficiency. Nature Genet 13:290–295 (1996).
  18. Huff V, Jaffe N, Saunders GF, Strong LC, Villalba F, Ruteshouser EC: WT1 exon 1 deletion/insertion mutations in Wilms tumor patients, associated with di- and trinucleotide repeats and deletion hotspot consensus sequences. Am J hum Genet 56:84–90 (1995).
  19. Ianzano L, D’Apolito M, Centra M, Savino M, Levran O, Auerbach AD, Cleton-Jansen AM, Dogget NA, Pronk JC, Tipping AG, Gibson RA, Mathew CG, Whitmore SA, Apostolou S, Callen DF, Zelante L, Savoia A: The genomic organization of the Fanconi anemia group A (FAA) gene. Genomics 41:309–314 (1997).
  20. Joenje H, Arwert F, Kwee ML, Madan K, Hoehn H: Confounding factors in the diagnosis of Fanconi anemia. Am J med Genet 79:403–405 (1998).
  21. Joenje H, Levitus M, Waisfisz Q, D’Andrea A, Garcia-Higuera I, Pearson T, van Berkel CG, Rooimans MA, Morgan N, Mathew CG, Arwert F: Complementation analysis in Fanconi anemia: assignment of the reference FA-H patient to group A. Am J hum Genet 67:759–762 (2000).
  22. Jonkman MF: Revertant mosaicism in human genetic disorders. Am J med Genet 85:361–364 (1999).
  23. Krawczak M, Cooper DN: Gene deletions causing human genetic disease: mechanisms of mutagenesis and the role of the local DNA sequence. Hum Genet 86:425–441 (1991).
  24. Levran O, Erlich T, Magdalena N, Gregory JJ, Batish SD, Verlander PC, Auerbach AD: Sequence variation in the Fanconi anemia gene FAA. Proc natl Acad Sci, USA 94:13051–13056 (1997).
  25. Lo Ten Foe JR, Kwee ML, Rooimans MA, Oostra AB, Veerman AJP, van Weel M, Pauli RM, Shahidi NT, Dokal I, Roberts I, Altay C, Gluckman E, Gibson RA, Mathew CG, Arwert F, Joenje H: Somatic mosaicism in Fanconi Anemia: Molecular basis and clinical significance. Eur J hum Genet 5:137–148 (1997).
  26. MacNeill EC, Hanenberg H, Pollok KE, van der Loo JC, Bierhuizen MF, Wagemaker G, Williams DA: Simultaneous infection with retroviruses pseudotyped with different envelope proteins bypasses viral receptor interference associated with colocalization of gp70 and target cells on fibronectin CH-296. J Virol 73:3960–3967 (1999).
  27. Miller AD, Garcia JV, von Suhr N, Lynch CM, Wilson C, Eiden MV: Construction and properties of retrovirus packaging cells based on gibbon ape leukemia virus. J Virol 65:2220–2224 (1991).
  28. Morgan NV, Tipping AJ, Joenje H, Mathew CG: High frequency of large intragenic deletions in the Fanconi anemia group A gene. Am J hum Genet 65:330–1341 (1999).

    External Resources

  29. Nolan GP: Phoenix cells. (1996).
  30. Pollok KE, Hanenberg H, Noblitt TW, Schroeder WL, Kato I, Emanuel D, Williams DA: High-efficiency gene transfer into normal and adenosine deaminase-deficient T lymphocytes is mediated by transduction on recombinant fibronectin fragments. J Virol 72:4882–4892 (1998).
  31. Poot M, Hoehn H, Kubbies M, Grossmann A, Chen Y, Rabinovitch PS: Cell-cycle analysis using continuous bromodeoxyuridine labeling and Hoechst 33358-ethidium bromide bivariate flow cytometry. Methods Cell Biol 41:327–340 (1994).
  32. Schroeder-Kurth TM, Auerbach AD, Obe G: Fanconi Anemia. Clinical, Cytogenetic and Experimental Aspects (Springer-Verlag, Heidelberg 1989).
  33. Seyschab H, Friedl R, Sun Y, Schindler D, Hoehn H, Hentze S, Schroeder-Kurth T: Comparative evaluation of diepoxybutane sensitivity and cell cycle blockage in the diagnosis of Fanconi anemia. Blood 85:2233–2237 (1995).
  34. Stephan V, Wahn V, le Deist F, Dirksen U, Broker B, Muller-Fleckenstein I, Horneff G, Schroten H, Fischer A, de Saint Basile G: Atypical X-linked severe combined immunodeficiency due to possible spontaneous reversion of the genetic defect in T cells. New Engl J Med 335:1563–1567 (1996).
  35. Strathdee CA, Gavish H, Shannon WR, Buchwald M: Cloning of cDNAs for Fanconi’s anemia by functional complementation. Nature 356:763–767 (1992).
  36. Thompson LH, Schild D: Recombinational DNA repair and human disease. Mutat Res 509:49–78 (2002)
  37. Wada T, Schurman SH, Otsu M, Garabedian EK, Ochs HD, Nelson DL, Candotti F: Somatic mosaicism in Wiskott-Aldrich syndrome suggests in vivo reversion by a DNA slippage mechanism. Proc natl Acad Sci, USA 98:8697–8702 (2001).
  38. Wahn V, Stephan V, Hirschhorn R: Reverse mutations – spontaneous amelioration or cure of inherited disorders? Eur J Pediatr 157:613–617 (1998).
  39. Waisfisz Q, Morgan NV, Savino M, de Winter JP, van Berkel CG, Hoatlin M, Ianzano L, Gibson RA, Arwert F, Savoia A, Mathew CG, Pronk J, Joenje H: Spontaneous functional correction of homozygous Fanconi anemia alleles reveals novel mechanistic basis for reverse mosaicism. Nature Genet 22:379–383 (1999).
  40. Wijker M, Morgan NV, Herterich S, van Berkel CGM, Tipping AJ, Gross HJ, Gille JJP, Pals G, Savino M, Altay C, Mohan S, Dokal I, Cavenagh J, Marsh J, van Weel M, Ortega JJ, Schuler D, Samochatova E, Karwacki M, Bekassy AN, Abecasis M, Ebell W, Kwee ML, de Ravel T, Mathew CG, et al: Heterogenous spectrum of mutations in the Fanconi anemia group A gene. Europ. J Hum Genet 7:52–59 (1999).

    External Resources

  41. Youssoufian H: Natural gene therapy and the Darwinian legacy. Nature Genet 13:255–256 (1996).

Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50